Open AccessEffects of carfilzomib alone and in combination with cisplatin on the cell death in cisplatin-sensitive and cisplatin-resistant ovarian carcinoma cell lines
Author(s) -
Sevda Zarei,
Javad Zavar Reza,
Hossein Zarei Jaliani,
Mohammad Reza Hajizadeh,
Saman Sargazi,
H. Hosseinian
Publication year - 2019
Publication title -
bratislavské lekárske listy/bratislava medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.387
H-Index - 32
eISSN - 1336-0345
pISSN - 0006-9248
DOI - 10.4149/bll_2019_075
Subject(s) - cisplatin , carfilzomib , ovarian cancer , cytotoxicity , pharmacology , efflux , cytotoxic t cell , cell culture , drug , cancer cell , chemosensitizer , cancer research , programmed cell death , chemistry , biology , proteasome inhibitor , cancer , medicine , apoptosis , in vitro , chemotherapy , biochemistry , genetics
Previous studies on the efficacy of platinum-based drugs and selective inhibitors of proteasome have revealed promising outcomes. This study is aimed to evaluate the effects of the combination of cisplatin and carfilzomib on the cell death induction and drug efflux transporters expression in cisplatin-sensitive (A2780s) and cisplatin-resistant (A2780cp) ovarian cancer cells lines.